Table 1.

Effect of apolipoprotein B silencing by mipomersen therapy (200 mg/weekly) on low-density lipoprotein-cholesterol levels (for details see Visser et al.⁴)

Patient population	Trial phase	Conventional lipid-lowering therapy	Duration of treatment (weeks)	Baseline LDL-C levels (mg/dL)	Change in LDL-C, %
Heterozygous FH	II	Y	6	207	−21
Heterozygous FH	II	Y	13	155	−22
High-CV risk statin-intolerant patients	II	N	26	244	−47
LDL-C ≥130 mg/dL	II	N	13	171	−45
Homozygous FH	III	Y	26	439	−25
Heterozygous FH (with CAD)	III	Y	26	153	−28
Severe hypercholesterolaemia	III	Y	26	276	−36
High CV risk	III	Y	26	123	−37

FH, familial hypercholesterolaemia; CAD, coronary artery disease; CV, cardiovascular.